In August 2016 it was announced that Advanced Cell Diagnostics, Inc. would be acquired by Bio-Techne Corporation (NASDAQ: TECH) in a primarily cash transaction with additional milestone payments. The firm now operates as a subsiduart of Bio-Techne. Advanced Cell Diagnostics (ACD) develops cell-and tissue-based diagnostic tests for personalized medicine: products and pharma assay services based on its proprietary RNAscope® technology, the first multiplex fluorescent and chromogenic in situ hybridization platform, capable of detecting and quantifying single molecules of RNA in situ. The company develops a portfolio of novel cancer diagnostic tests for the management of various ontological diseases, including head and neck cancer, cervical cancer, B-cell lymphoma, melanoma, breast cancer, and circulating tumor cells. It offers RNAscope formalin-fixed and paraffin-embedded (FFPE) assay kit that is designed to detect RNA biomarkers in routine FFPE tissue specimens with single molecule sensitivity and at single cell resolution. The company also provides clinical-grade assay development and biomarker analysis services to speed up biomarker validation; and companion diagnostic development, custom assay development, biomarker analysis, and clinical trial support services. It partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. Advanced Cell Diagnostics, Inc. was founded in 2007 and is based in Hayward, California
